multipl catalyst leadership chang modul pt
gener pro-forma share cash includ share net
proce recent secondari offer
enter rich vein catalyst
expect sever key value-driv catalyst replimun stock
phase data bristol-my squibb rate
opdivo melanoma non-melanoma skin cancersha read-
potenti on-going phase registr trial examin
regeneron rate libtayo cutan squamou
cell carcinoma cscc phase data
opdivo urotheli carcinoma msi-h cancer result
phase trial examin libtayo cscc transplant
patient initi result phase trial examin
/- opdivo result phase
trial examin rate t-vec plu
merck co rate checkpoint inhibitor keytruda
melanoma also point replimun manufactur
facilitywhich abl support full commerci
product candidatesi slate becom oper
accordingli reiter buy rate reduc
price target base dilut recent
secondari offer continu view replimun posit solidli
vanguard oncolyt viru ov develop
leadership chang reflect compani progress view
recent robert coffin ph elect transit current
role ceo take newly-cr role presid chief
research develop offic philip astley-sparkea board
member replimun former ceo biovexshal becom
ceo believ transit make sens compani continu
make signific progress clinic develop front
valuat risk util discount cash flow dcf -base
analysi valu replimun share core assumpt compris
discount rate effect tax rate probabl
approv melanoma probabl approv
candid cscc ad cash hand
deriv market valu price per share base
share outstand risk includ
limit inabl gener compel efficaci safeti data
proof-of-concept clinic trial melanoma cscc
failur achiev favor result pivot trial inabl
obtain regulatori approv lack success partnership
establish firm spur commerci uptak post-
approv failur deliv promis early-stag pipelin
ov candid medium- long-term dilut risk
definit distribut analyst rate analyst certif disclosur pleas refer page report
thousand except per share data
compani report wainwright co estim
fy sales- royalti fee revenues- total revenue- expensescost sales- research gener sell marketing- total gain loss income/expenseresearch develop invest interest incom chang fair valu warrant incom expens total invest incom loss benefit provis incom benefit provis incom taxes- net incom accret redeem convert prefer stock redempt value- net incom loss attribut common net loss per share net loss per share weight averag number share outstand weight averag number share outstand fy replimun group inc
materi confidenti intend use institut account defin finra rule may also
privileg otherwis protect work product immun legal rule receiv mistak pleas let
us know email repli delet system may copi messag
disclos content anyon integr secur messag guarante internet
 wainwright co llc rate wainwright employ three tier rate system evalu
potenti return risk associ own common equiti share rate firm expect return given
equiti measur rel basi compani sector price object calcul estim
potenti movement price given equiti could reach provid certain target met defin time horizon
price object subject extern factor includ industri event market volatil
market outperform buy common stock compani expect outperform passiv index compris
common stock compani within sector
market perform neutral common stock compani expect mimic perform passiv index
compris common stock compani within sector
market under-perform sell common stock compani expect under-perform passiv index compris
common stock compani within sector
rate price target histori replimun group inc repl-u
invest bank servic includ limit act manager/co-manag underwrit placement
secur act financi advisor and/or provid corpor financ capit markets-rel servic compani
one affili subsidiari within past month
distribut rate tabl januari
 wainwright co llc firm member finra sipc regist broker-deal
robert burn raghuram selvaraju ph certifi view express report accur reflect
person view subject secur issuer discuss part compens
directli indirectli relat specif recommend view express research report neither
member household offic director advisori board member compani
none research analyst research analyst household financi interest secur
inc includ without limit option right warrant futur long short posit
decemb neither firm affili benefici class common equiti secur
inc
neither research analyst firm know reason know materi conflict interest time
public research report
research analyst princip respons prepar report receiv compens base upon
specif invest bank servic transact compens base factor includ total revenu profit
firm substanti portion deriv invest bank servic
firm affili receiv compens inc invest bank servic within twelv
month seek compens compani mention report invest bank servic within
three month follow public research report
firm make market inc date research report
secur compani discuss report may unsuit investor depend specif invest
object financi posit past perform guarante futur result report offer inform
purpos constitut offer solicit buy sell secur discuss herein jurisdict
would prohibit research report intend provid tax advic use provid tax advic
person electron version wainwright co llc research report made avail client simultan
part report may reproduc form without express permiss wainwright co llc addit
 wainwright co llc provid individu tailor invest advic research report research report
intend provid person invest advic take account specif invest object financi
situat particular need specif person investor seek financi advic regard appropri
invest financi instrument implement invest strategi discuss recommend research report
 wainwright co llc affili salespeopl trader profession may provid oral written market
commentari trade strategi reflect opinion contrari opinion express research report
 wainwright co llc affili offic director employe exclud analyst time time
long short posit act princip buy sell secur deriv includ option warrant
thereof cover compani refer research report
inform contain herein base sourc believ reliabl guarante us
accur purport complet statement summari avail data compani industri secur
discuss report opinion estim includ report constitut analyst judgment date
report subject chang without notic
secur financi instrument discuss research report may lose valu insur feder
deposit insur corpor subject invest risk includ possibl loss princip amount invest
